Neoplastic Meningitis From Systemic Malignancies: Diagnosis, Prognosis and Treatment

Seminars in Oncology

Volumn 33, Issue 3, 2006, Pages 312-323

  Jaeckle, Kurt A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE DERIVATIVE; CYTARABINE; DIAZIQUONE; ETOPOSIDE; FLOXURIDINE; GEMCITABINE; IODINE 131; MAFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; NIMUSTINE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; THYMIDINE KINASE; TOPOTECAN; TRASTUZUMAB; TRIMETREXATE;

AGE DISTRIBUTION; ARACHNOIDITIS; ARTICLE; BRAIN DISEASE; BREAST CARCINOMA; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVOR; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; CRANIAL NEUROPATHY; HEADACHE; HUMAN; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; LYMPHOMA; MELANOMA; MENINGEAL BIOPSY; NAUSEA; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STANDARDIZATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOMA; MELANOMA; MENINGITIS; PALLIATIVE CARE; PARANEOPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL RATE;

EID: 33744942620     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.04.016     Document Type: Article

References (108)

1. Chamberlain M.C. Carcinomatous meningitis. Arch Neurol 54 (1997) 16-17
2. Grossman S.A., and Krabak M.J. Leptomeningeal carcinomatosis. Cancer Treat Rev 25 (1999) 103-119
3. Chamberlain M.C., and Kormanik P.A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 54 (1997) 1364-1368
4. Chamberlain M.C., and Kormanik P.R. Carcinomatous meningitis secondary to breast cancer. Predictors of response to combined modality therapy. J Neurooncol 35 (1997) 55-64
5. Balm M., and Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 53 (1996) 626-632
6. Fizazi K., Asselain B., Vincent-Salomon A., et al. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77 (1996) 1315-1323
7. Jayson G.C., and Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 7 (1996) 773-786
8. NCCN Adult Brain Tumor Practice Guidelines. Oncology 11 (1997) 237-277
9. Grassi M.A., and Lee A.G. Lymphomatous meningitis of the Burkitt type presenting with multiple cranial neuropathies. Am J Ophthalmol 133 (1992) 424-425
10. Nugent J.L., Bunn Jr. P.A., Matthews M.J., et al. CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival. Cancer 44 (1979) 1885-1893
11. Wasserstrom W.R., Glass J.P., and Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors. Experience with 90 patients. Cancer 49 (1982) 759-772
12. Kaplan J.G., DeSouza T.G., Farkash A., et al. Leptomeningeal metastases. comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9 (1990) 225-229
13. Wasserstrom W.R., Glass J.P., and Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors. Experience with 90 patients. Cancer 49 (1982) 759-772
14. Little J.R., Dale A.J., and Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 30 (1974) 138-143
15. Shapiro W.R., Posner J.B., Ushio Y., et al. Treatment of meningeal neoplasms. Cancer Treat Rep 61 (1977) 733-743
16. Rosen S.T., Aisner J., Makuch R.W., et al. Carcinomatous leptomeningitis in small cell lung cancer. A clinicopathologic review of the National Cancer Institute experience. Medicine 61 (1982) 45-53
17. Amer M.H., Al Sarraf M., Baker L.H., et al. Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival. Cancer 42 (1978) 660-668
18. Gonzalez-Vitale J.C., and Garcia-Bunuel R. Meningeal carcinomatosis. Cancer 37 (1976) 2906-2911
19. Chamberlain M.C. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 38 (1998) 135-140
20. Rosen S.T., Aisner J., Makuch R.W., et al. Carcinomatous leptomeningitis in small cell lung cancer. A clinicopathologic review of the National Cancer Institute experience. Medicine 61 (1982) 45-53
21. Yap H.Y., Yap B.S., Tashima C.K., et al. Meningeal carcinomatosis in breast cancer. Cancer 42 (1978) 283-286
22. Amer M.H., Al Sarraf M., Baker L.H., et al. Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival. Cancer 42 (1978) 660-668
23. Kaplan J.G., DeSouza T.G., Farkash A., et al. Leptomeningeal metastases. comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9 (1990) 225-229
24. Stemmler H.J., Schmitt M., Harbeck N., et al. Application of intrathecal trastuzumab (Herceptin) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15 (2006) 1373-1377
25. Chamberlain M.C., Sandy A.D., and Press G.A. Leptomeningeal metastasis. A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40 (1990) 435-438
26. Glass J.P., Melamed M., Chernik N.L., et al. Malignant cells in cerebrospinal fluid (CSF). The meaning of a positive CSF cytology. Neurology 29 (1979) 1369-1375
27. Glantz M.J., Cole B.F., Glantz L.K., et al. Cerebrospinal fluid cytology in patients with cancer. Minimizing false-negative results. Cancer 82 (1998) 733-739
28. Wasserstrom W.R., Schwartz M.K., Fleisher M., et al. Cerebrospinal fluid biochemical markers in central nervous system tumors. A review. Ann Clin Lab Sci 11 (1981) 239-251
29. van Zanten A.P., Twijnstra A., Hart A.A., et al. Cerebrospinal fluid lactate dehydrogenase activities in patients with central nervous system metastases. Clin Chim Acta 161 (1986) 259-268
30. Twijnstra A., Ongerboer de Visser B.W., van Zanten A.P., et al. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 7 (1989) 57-63
31. Stockhammer G., Poewe W., Burgstaller S., et al. Vascular endothelial growth factor in CSF. A biological marker for carcinomatous meningitis. Neurology 54 (2000) 1670-1676
32. Chamberlain M.C. Cytologically negative carcinomatous meningitis. Usefulness of CSF biochemical markers. Neurology 50 (1998) 1173-1175
33. van Oostenbrugge R.J., Hopman A.H., Ramaekers F.C., et al. In situ hybridization. A possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 38 (1998) 127-133
34. Hovestadt A., Henzen-Logmans S.C., and Vecht C.J. Immunohistochemical analysis of the cerebrospinal fluid for carcinomatous and lymphomatous leptomeningitis. Br J Cancer 62 (1990) 653-654
35. Rhodes C.H., Glantz M.J., Glantz L., et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 77 (1996) 543-548
36. Rogers L.R., Duchesneau P.M., Nunez C., et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 42 (1992) 1239-1241
37. Cheng T.M., O'Neill B.P., Scheithauer B.W., et al. Chronic meningitis. The role of meningeal or cortical biopsy. Neurosurgery 34 (1994) 590-595
38. Schumacher M., and Orszagh M. Imaging techniques in neoplastic meningiosis. J Neurooncol 38 (1998) 111-120
39. Chamberlain M.C., Sandy A.D., and Press G.A. Leptomeningeal metastasis. A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40 (1990) 435-438
40. Freilich R.J., Krol G., and DeAngelis L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38 (1995) 51-57
41. Chamberlain M.C. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 38 (1998) 135-140
42. Glantz M.J., Hall W.A., Cole B.F., et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75 (1995) 2919-2931
43. Chamberlain M.C., and Kormanik P.A. Prognostic significance of 111 indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46 (1996) 1674-1677
44. 111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 50 (1998) 438-444
45. 111Indium-DTPA CSF flow studies. Neurology 41 (1991) 1765-1769
46. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 52 (1999) 216-217
47. Iskandar B.J., and Haughton V. Age-related variations in peak cerebrospinal fluid velocities in the foramen magnum. J Neurosurg 103 (2005) 508-511
48. DeAngelis L.M. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 38 (1998) 245-252
49. Hildebrand J. Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood. J Neurooncol 38 (1998) 193-198
50. Kuo A.H., Yataganas X., Galicich J.H., et al. Proliferative kinetics of central nervous system (CNS) leukemia. Cancer 36 (1975) 232-239
51. Blasberg R.G. Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat Rep 61 (1977) 625-631
52. Blasberg R.G., Patlak C., and Fenstermacher J.D. Intrathecal chemotherapy. Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195 (1975) 73-83
53. Shapiro W.R., Young D.F., and Mehta B.M. Methotrexate. Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293 (1975) 161-166
54. Blasberg R.G., Patlak C., and Fenstermacher J.D. Intrathecal chemotherapy. Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195 (1975) 73-83
55. Chamberlain M.C., and Kormanik P.A. Prognostic significance of 111 indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46 (1996) 1674-1677
56. Glantz M.J., Jaeckle K.A., Chamberlain M.C., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 (1999) 3349-3351
57. Glantz M.J., LaFollette S., Jaeckle K.A., et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17 (1999) 3110-3116
58. Jaeckle K.A., Phuphanich S., Bent M.J., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84 (2001) 157-163
59. Grossman S.A., Finkelstein D.M., Ruckdeschel J.C., et al., Eastern Cooperative Oncology Group. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 11 (1993) 561-569
60. Iacoangeli M., Roselli R., Pagano L., et al. Intrathecal chemotherapy for treatment of overt meningeal leukemia. Comparison between intraventricular and traditional intralumbar route. Ann Oncol 6 (1995) 377-382
61. Berweiler U., Krone A., and Tonn J.C. Reservoir systems for intraventricular chemotherapy. J Neurooncol 38 (1998) 141-143
62. Sandberg D.I., Bilsky M.H., Souweidane M.M., et al. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47 (2000) 49-54
63. Chamberlain M.C., Kormanik P.A., and Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87 (1997) 694-699
64. Perrin R.G., Lishner M., and Guha A. Experience with Ommaya reservoir in 120 consecutive patients with meningeal malignancy. Can J Neurol Sci 17 (1990) 190-192
65. Duffner P.K. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10 (2004) 293-310
66. Lai R., Abrey L.E., Rosenblum M.K., et al. Treatment-induced leukoencephalopathy in primary CNS lymphoma. A clinical and autopsy study. Neurology 62 (2004) 451-456
67. Siegal T. Leptomeningeal metastases. Rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?. J Neurooncol 38 (1998) 151-157
68. Orlando L., Curigliano G., Colleoni M., et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 22 (2002) 3057-3059
69. Kim D.Y., Lee K.W., Yun T., et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor. Methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33 (2003) 608-612
70. Hitchins R.N., Bell D.R., Woods R.L., et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5 (1987) 1655-1662
71. Kern D.H., Shoemaker R.H., Hildebrand-Zanki S.U., et al. Structure-activity relationships defining the cytotoxicity of catechol analogues against human malignant melanoma. Cancer Res 48 (1988) 5178-5182
72. Kochi K., Kuratsu J., Mihara Y., et al. Ventriculolumbar perfusion of 3-[4-amino-2-methyl-5-pyrimidinylmethyl]-1-nitrosourea hydrochloride. Neurosurgery 33 (1993) 817-823
73. Kitamura I., Kochi M., Matsumoto Y., et al. Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis. An experimental study. Cancer Res 56 (1996) 3982-3986
74. Chatelut E., Kim T., and Kim S. A slow-release methotrexate formulation for intrathecal chemotherapy. Cancer Chemother Pharmacol 32 (1993) 179-182
75. Chamberlain M.C., Kormanik P., and Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52 (1995) 912-917
76. Esteva F.J., Soh L.T., Holmes F.A., et al. Phase II trials and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases form breast cancer. Cancer Chemother Pharmacol 46 (2000) 382-386
77. Zimm S., Collins J.M., Miser J., et al. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 35 (1984) 826-830
78. Jaeckle K.A., Phuphanich S., Bent M.J., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84 (2001) 157-163
79. Nakagawa H., Miyahara E., and Suzuki T. Continuous intrathecal administration of 5-fluoro-2′-deoxyuridine for the treatment of neoplastic meningitis 1. Neurosurgery 57 (2005) 266-280
80. Blaney S.M., Heideman R., Berg S., et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 21 (2003) 243-247
81. Groves M.D., Baumgartner K.E., Conrad C.A., et al. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neurology 62 (2004) 475 (abstr)
82. Fuchs H.E., Archer G.E., Colvin O.M., et al. Activity of intrathecal 4- hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 15 (1990) 1954-1959
83. Slavc I., Schuller E., Czech T., et al. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 38 (1998) 213-218
84. Slavc I., Schuller E., Falger J., et al. Feasibility of long-term intraventricular therapy with mafosfamide (n=26) and etoposide (n=11). Experience in 26 children with disseminated malignant brain tumors. J Neurooncol 64 (2003) 239-247
85. Blaney S.M., Balis F.M., Berg S., et al. Intrathecal mafosfamide. A preclinical pharmacology and phase I trial. J Clin Oncol 23 (2005) 1555-1563
86. Chen Y.M., Chen M.C., Tsai C.M., et al. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis-A case report. Lung Cancer 40 (2003) 99-101
87. Chamberlain M.C., Tsao-Wei D.D., and Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 106 (2006) 2021-2027
88. Nakagawa H., Tamura M., Fukushima S., et al. Continuous intrathecal chemotherapy with 5-fluoro-2′-deoxyuridine (FdUrd) in treatment of leptomeningeal carcinomatosis. Proc Am Soc Clin Oncol 23 (2004) 123 (abstr)
89. Chamberlain M.C. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 15 (2002) 2675-2680
90. Schulz H., Pels H., Schmidt-Wolf I., et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89 (2004) 753-754
91. Laufman L.R., and Forsthoefel K.F. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. (letter). Clin Breast Cancer 2 (2002) 316
92. Bergman I., Barmada M.A., Heller G., et al. Treatment of neoplastic meningeal xenografts; intraventricular administration of an anti-ganglioside monoclonal antibody, 3F8. Int J Cancer 12 (1999) 538-548
93. Bigner D.D., Archer G.E., McLendon R.E., et al. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin Cancer Res 1 (1995) 1545-1555
94. Hall W.A., Myklebust A., Godal A., et al. In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery 34 (1994) 649-655
95. Wong F., Groves M., Conrad C., et al. A phase I study of intraventricular injection of I-131 sodium iodide in patients with leptomeningeal metastases. Neurology 66 (2006) (abstr EV 6.002)
96. Cokgor I., Akabani G., Friedman H.S., et al. Long term response in a patient with neoplastic meningitis secondary to melanoma treated with Mel-14 F(ab')(2). A case study. Cancer 91 (2001) 1809-1813
97. Bigner D.D., Brown M., Coleman R.E., et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131-I- radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 F(ab′)2-a preliminary report. J Neurooncol 24 (1995) 109-122
98. Coakham H.B., and Kemshead J.T. Treatment of neoplastic meningitis by targeted radiation using (131)I - radiolabeled monoclonal antibodies. Results of responses and long term follow-up in forty patients. J Neurooncol 38 (1998) 225-232
99. Berg S.L., and Chamberlain M.C. Current treatment of leptomeningeal metastases. Systemic chemotherapy, intrathecal chemotherapy, and symptom management. In: Abrey L.E., Chamberlain M.C., and Engelhard H.H. (Eds). Leptomeningeal Metastases (2005), Springer, New York, NY 121-146
100. Tetef M.L., Margolin K.A., Doroshow J.H., et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46 (2000) 19-26
101. Glantz M.J., Cole B.F., Recht L., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer. Is intrathecal chemotherapy necessary?. J Clin Oncol 16 (1998) 1561-1567
102. Rogers L.R., Remer S.E., and Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neurooncol 6 (2004) 63-64
103. Giglio P., Tremont-Lukats I.W., and Groves M.D. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 65 (2003) 167-172
104. Friedman H.S. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol 27 suppl 6 (2000) 35-40
105. Driesse M.J., Esandi M.C., Kros J.M., et al. Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther 7 (2000) 1401-1409
106. Vincent A.J., Esandi M.D., can Someren G., et al. Long term survival in a rat model using a recombinant adenovirus containing the HSV-TK gene. J Neurosurg 85 (1996) 648-654
107. Siegal T., Lossos A., and Pfeffer M.R. Leptomeningeal metastases. Analyses of 31 patients with sustained off-therapy response following combined modality therapy. Neurology 44 (1994) 1463-1469
108. Chamberlain M.C. Neoplastic meningitis. Semin Neurol 24 (2004) 363-374